Controlling the properties and behavior of matter at the smallest scale—in effect, "domesticating atoms"—can help to overcome some of the world’s biggest challenges, concludes a new report on how diverse experts view the future of nanotechnology. Released today, NanoFrontiers: Visions for the Future of Nanotechnology, summarizes discussions among over 50 scientists, engineers, ethicists, policymakers, and other experts, as well as information gathered in follow-up interviews and from specially prepared background papers, about the long-term potential of nanotechnology.
A new study says targeting smaller (¡Ü5 mm) lesions does little to significantly reduce the incidence of colorectal cancer (CRC) and, in fact, results in extremely high financial costs and a large proportion of adverse events. Published in the June 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, a cost-benefit analysis study says the low malignancy rate among so-called diminutive polyps gives virtual colonoscopy with removal of lesions 6 mm or greater the best estimated value per life year gained and with fewer complications.
Medical professionals conducting clinical trials should provide more information about financial conflicts of interest before they talk to patients about participating in the trials.
That is one of the main conclusions of a new survey by researchers from Duke University Medical Center and Johns Hopkins University. Their study found that 41 percent of the clinical trial coordinators surveyed had experience disclosing financial aspects of the trial to potential participants, and 28 percent of the coordinators had been asked by participants about potential financial conflicts.
Scientists have discovered one of the reasons why bladder cancer is so much more prevalent in men than women: A molecular receptor or protein that is much more active in men than women plays a role in the development of the disease. The finding could open the door to new types of treatment with the disease.
Crohn’s disease is a chronic relapsing inflammatory disorder of the intestinal tract that affects an estimated 0.15% of people in the developed world. Common symptoms include abdominal pain and diarrhea, but the disorder is often associated with debilitating clinical complications. Researchers from the University of Liège, Belgium, have now uncovered an important clue to the susceptibility of individuals to this disease.
Using a new type of drug that targets a specific genetic defect, researchers at the University of Pennsylvania School of Medicine, along with colleagues at PTC Therapeutics Inc. and the University of Massachusetts Medical School, have for the first time demonstrated restoration of muscle function in a mouse model of Duchenne's muscular dystrophy (DMD).
Mayo Clinic researchers, along with collaborators from the National Institutes of Health (NIH) and University of Oslo, Norway, have discovered that a miscue of the body’s genetic repair system may cause Huntington’s disease, a fatal condition that affects 30,000 Americans annually by destroying their nervous system. Until now, no one knew how Huntington’s begins, only that it is incurable. The findings appear in the online issue of the journal Nature.
Cilia, tiny hair-like structures that propel mucus out of airways, have to agree on the direction of the fluid flow to get things moving. Researchers at the Salk Institute for Biological Studies discovered a novel two-step mechanism that ensures that all cilia beat in unison.
An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows.
The findings suggest that a drug that can block this "survival protein" might on its own be an effective therapy.
But such a drug used in combination with several existing drugs might also offer an effective one-two punch against drug-resistant forms of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). The two forms of cancer kill about 20,500 Americans yearly.
The most recent census of mountain gorillas in Uganda’s Bwindi Impenetrable National Park—one of only two places in the world where the rare gorillas exist—has found that the population has increased by 6 percent since the last census in 2002, according to the Uganda Wildlife Authority, the Wildlife Conservation Society, the Max Planck Institute of Anthropology and other groups that participated in the effort.